
    
      Eligible subjects will be identified prior to surgery. On the day of surgery, each patient
      will be randomized to be in either Local infiltration of bupivacaine OR liposomal
      bupivacaine. Study will be double blinded to patients and Investigators. Patients assigned to
      the local infiltration with bupivacaine group will receive a total 60 ml of 0.25% bupivacaine
      with 30 ml delivered to each breast. Patients assigned to the local infiltration of liposomal
      bupivacaine will receive a total of 20 ml liposomal bupivacaine (266 mg) with 10 ml of 0.25%
      bupivacaine and 30 ml of 0.9% sodium chloride. These injections will occur at the end of the
      mastectomy and prior to the insertion of the tissue expander implant. After this
      intraoperative injection, patients will not receive any more doses of local anesthetics.
    
  